Cargando…

Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome

INTRODUCTION: Adults with Down syndrome (DS) are at increased risk for Alzheimer's disease (AD) and vary in their age of transition from AD preclinical to prodromal or more advanced clinical stages. An empirically based method is needed to determine individual “estimated years from symptom onse...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverman, Wayne, Krinsky‐McHale, Sharon J., Kovacs, Cynthia, Lee, Joseph H., Listwan, Tracy, Pang, Deborah I., Zigman, Warren B., Schupf, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300244/
https://www.ncbi.nlm.nih.gov/pubmed/37389223
http://dx.doi.org/10.1002/dad2.12444
_version_ 1785064544248266752
author Silverman, Wayne
Krinsky‐McHale, Sharon J.
Kovacs, Cynthia
Lee, Joseph H.
Listwan, Tracy
Pang, Deborah I.
Zigman, Warren B.
Schupf, Nicole
author_facet Silverman, Wayne
Krinsky‐McHale, Sharon J.
Kovacs, Cynthia
Lee, Joseph H.
Listwan, Tracy
Pang, Deborah I.
Zigman, Warren B.
Schupf, Nicole
author_sort Silverman, Wayne
collection PubMed
description INTRODUCTION: Adults with Down syndrome (DS) are at increased risk for Alzheimer's disease (AD) and vary in their age of transition from AD preclinical to prodromal or more advanced clinical stages. An empirically based method is needed to determine individual “estimated years from symptom onset (EYO),” the same construct used in studies of autosomal dominant AD . METHODS: Archived data from a previous study of > 600 adults with DS were examined using survival analysis methods. Age‐specific prevalence of prodromal AD or dementia, cumulative risk, and EYOs were determined. RESULTS: Individualized EYOs for adults with DS ranging in age from 30 to 70+ were determined, dependent upon chronological age and clinical status. DISCUSSION: EYOs can be a useful tool for studies focused on biomarker changes during AD progression in this and other populations at risk, studies that should contribute to improved methods for diagnosis, prediction of risk, and identification of promising treatment targets. HIGHLIGHTS: Years from Alzheimer's disease (AD) onset (EYO) was estimated for adults with Down syndrome (DS). EYOs were informed by AD clinical status and age, ranging from 30 to > 70 years. Influences of biological sex and apolipoprotein E genotype on EYOs were examined. EYOs have advantages for predicting risk of AD‐related dementia compared to age. EYOs can be extremely informative in studies of preclinical AD progression.
format Online
Article
Text
id pubmed-10300244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103002442023-06-29 Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome Silverman, Wayne Krinsky‐McHale, Sharon J. Kovacs, Cynthia Lee, Joseph H. Listwan, Tracy Pang, Deborah I. Zigman, Warren B. Schupf, Nicole Alzheimers Dement (Amst) Research Articles INTRODUCTION: Adults with Down syndrome (DS) are at increased risk for Alzheimer's disease (AD) and vary in their age of transition from AD preclinical to prodromal or more advanced clinical stages. An empirically based method is needed to determine individual “estimated years from symptom onset (EYO),” the same construct used in studies of autosomal dominant AD . METHODS: Archived data from a previous study of > 600 adults with DS were examined using survival analysis methods. Age‐specific prevalence of prodromal AD or dementia, cumulative risk, and EYOs were determined. RESULTS: Individualized EYOs for adults with DS ranging in age from 30 to 70+ were determined, dependent upon chronological age and clinical status. DISCUSSION: EYOs can be a useful tool for studies focused on biomarker changes during AD progression in this and other populations at risk, studies that should contribute to improved methods for diagnosis, prediction of risk, and identification of promising treatment targets. HIGHLIGHTS: Years from Alzheimer's disease (AD) onset (EYO) was estimated for adults with Down syndrome (DS). EYOs were informed by AD clinical status and age, ranging from 30 to > 70 years. Influences of biological sex and apolipoprotein E genotype on EYOs were examined. EYOs have advantages for predicting risk of AD‐related dementia compared to age. EYOs can be extremely informative in studies of preclinical AD progression. John Wiley and Sons Inc. 2023-06-27 /pmc/articles/PMC10300244/ /pubmed/37389223 http://dx.doi.org/10.1002/dad2.12444 Text en © 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Silverman, Wayne
Krinsky‐McHale, Sharon J.
Kovacs, Cynthia
Lee, Joseph H.
Listwan, Tracy
Pang, Deborah I.
Zigman, Warren B.
Schupf, Nicole
Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title_full Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title_fullStr Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title_full_unstemmed Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title_short Individualized estimated years from onset of Alzheimer's disease– related decline for adults with Down syndrome
title_sort individualized estimated years from onset of alzheimer's disease– related decline for adults with down syndrome
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300244/
https://www.ncbi.nlm.nih.gov/pubmed/37389223
http://dx.doi.org/10.1002/dad2.12444
work_keys_str_mv AT silvermanwayne individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT krinskymchalesharonj individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT kovacscynthia individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT leejosephh individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT listwantracy individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT pangdeborahi individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT zigmanwarrenb individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome
AT schupfnicole individualizedestimatedyearsfromonsetofalzheimersdiseaserelateddeclineforadultswithdownsyndrome